Modelling immunization strategies with cytomegalovirus vaccine candidates

Epidemiology and Infection

Volumn 139, Issue 12, 2011, Pages 1818-1826

  Azevedo, R S ^a   Amaku, M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cytomegalovirus vaccine; immunity waning; immunization strategies; modelling

Indexed keywords

CYTOMEGALOVIRUS VACCINE;

ADULT; ARTICLE; CHILD; CONGENITAL INFECTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; HUMAN; IMMUNITY WANING; IMMUNOLOGICAL PARAMETERS; INCIDENCE; INFANT; MATHEMATICAL MODEL; PHASE 2 CLINICAL TRIAL (TOPIC); SEROPREVALENCE; VACCINATION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGE FACTORS; BRAZIL; CHILD; COMPUTER SIMULATION; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; HUMANS; INFANT; MODELS, IMMUNOLOGICAL; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 80255136306     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268811000343     Document Type: Article

References (19)

1. Almeida LNB, et al. Cytomegalovirus seroepidemiology in an urban community of São Paulo, Brazil. Revista de Saude Publica 2001; 35: 124-129.
2. Fang FQ, et al. Incidence of cytomegalovirus infection in Shanghai, China. Clinical and Vaccine Immunology 2009; 16: 1700-1703.
3. Coonrod D, et al. Association between cytomegalovirus seroconversion and upper genital tract infection among women attending a sexually transmitted disease clinic: a prospective study. Journal of Infectious Diseases 1998; 177: 1188-1193.
4. Plotkin SA. Congenital cytomegalovirus infection and its prevention. Clinical Infectious Diseases 2004; 38: 1038-1039.
5. Porath A, et al. Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease. Reviews of Infectious Diseases 1990; 12: 31-40.
6. Pass RF, et al. Vaccine prevention of maternal cytomegalovirus infection. New England Journal of Medicine 2009; 360: 1191-1199.
7. Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 2001; 19: 1356-1362.
8. Amaku M, et al. Vaccination against rubella: Analysis of the temporal evolution of the agedependent force of infection and the effects of different contact patterns. Physical Reviews E 2003; 67: 051907.
9. Amaku M, Azevedo RS. Estimating the true incidence of rubella. Mathematical Population Studies 2010; 17: 91-100.
10. Fernandes GCVR, et al. Seroepidemiology of Toxoplasma infection in a metropolitan region of Brazil. Epidemiology and Infection 2009; 137: 1809-1815.
11. Plotkin SA. Cytomegalovirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia: Saunders Elsevier, 2008, pp. 1147-1154.
12. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. Philadelphia: Saunders Elsevier, 2008, pp. 631-685.
13. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Reviews in Medical Virology 2007; 17: 253-276.
14. WHO Executive Board. 2009 Global Elimination of Measles Report EB125/4 (http://apps.who.int/gb/ ebwha/pdf-files/EB125/B125-4-en.pdf). Accessed 2 March 2010.
15. Farrington CP. Modelling forces of infection for measles, mumps and rubella. Statistics in Medicine 1990; 9: 953-967.
16. Lübeck PR, Doerr HW, Rabenau HF. Epidemiology of human cytomegalovirus (HCMV) in an urban region ofGermany: what has changed? Medical Microbiology and Immunology 2010; 199: 53-60.
17. Cui X, et al. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008; 26: 5760-5766.
18. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. Journal of the American Medical Association 2003; 289: 1008-1011.
19. Yamamoto AY, et al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. American Journal of Obstetrics and Gynecology 2010; 202: 297.e1-8.